Great news for MSB today as well, 100 day survival data in their paediatric phase 3 GVHD trial. Overall survival after 100 days of 75%. Smaller numbers in the CYP studies being phase 1, but definitely promising greater efficacy.... Good luck to MSB with getting their product to market, hopefully CYP won't be too far behind, at a drastically reduced cost.
Ann: Positive 28-day Clinical Trial Data in Cohort B, page-15
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $45.16M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.0¢ | $8.331K | 33.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9971 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 1054 | 2 |
View Market Depth
| Last trade - 11.22am 11/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |